Calisra Biotech

HOME

TEAM

PORTFOLIO

CONTACT

PORTFOLIO

Calisra Biotech is a founding investor in the following companies:

Proteio, Inc. applies a proprietary in vivo metabolic labeling technology to measure the turnover of specific proteins as diagnostic biomarkers. Proteio is employing its technology to develop clinical diagnostics to measure effectiveness of therapies in treating atherosclerosis and other diseases.